VE 818
Alternative Names: VE-818Latest Information Update: 30 Nov 2023
At a glance
- Originator Vedanta Biosciences
- Class Bacteria
- Mechanism of Action Gastrointestinal microbiome modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Unspecified
Most Recent Events
- 28 Nov 2023 Vedanta Biosciences has patent protection for cover compositions of clostridia bacterial species in European Union
- 24 May 2022 Phase-I clinical trials in Unspecified (In volunteers) in USA (PO) before May 2022
- 24 May 2022 Efficacy and adverse events data from phase I trial in healthy volunteers released by Vedanta Biosciences